BRAF Status in Personalizing Treatment Approaches for Pediatric Gliomas.

ABSTRACT:

Purpose

Alteration of the BRAF/MEK/MAPK pathway is the hallmark of pediatric low-grade gliomas (PLGGs), and mTOR activation has been documented in the majority of these tumors. We investigated combinations of MEK1/2, BRAF^V600E and mTOR inhibitors in gliomas carrying specific genetic alterations of the MAPK pathway.

Experimental design

We used human glioma lines containing BRAF^V600E (adult high-grade: AM-38, DBTRG, PLGG: BT40), or wild-type BRAF (pediatric high-grade: SF188, SF9427, SF8628) and isogenic systems of KIAA1549:BRAF-expressing NIH/3T3 cells and BRAF^V600E-expressing murine brain cells. Signaling inhibitors included everolimus (mTOR), PLX4720 (BRAF^V600E), and AZD6244 (MEK1/2). Proliferation was determined using ATP-based a

SUBMITTER: Olow A 

PROVIDER: S-EPMC5093033 | biostudies-literature | 2016 Nov

REPOSITORIES: biostudies-literature